EUCTR2011-006310-13-DE进行中（未招募）1 期
CAO/ARO/AIO-12: Induction chemotherapy before or after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer:A randomized phase II trial of the German Rectal Cancer Study Group - CAO/ARO/AIO-12
niversity Hospital Frankfurt, Goethe University0 个研究点目标入组 304 人开始时间: 2014年10月17日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 304
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male and female patients with histologically confirmed diagnosis of rectal adenocarcinoma localised 0 – 12 cm from the anocutaneous line as measured by rigid rectoscopy (i.e. lower and middle third of the rectum)
- •Staging requirements: High-resolution, thin-sliced (i.e. 3mm) magnetic resonance imaging (MRI) of the pelvis is the mandatory local staging procedure.
- •MRI-defined inclusion criteria: presence of at least one of the following high-risk conditions:
- •- any cT3 if the distal extent of the tumor is < 6 cm from the anocutaneous line, or
- •- cT3 in the middle third of the rectum (= 6-12 cm) with MRI evidence of extramural tumor spread into the mesorectal fat of more than 5 mm (>cT3b), or
- •- resectable cT4 tumors, or
- •- any clear cN+ based on MRI-criteria (see appendix)
- •Trans-rectal endoscopic ultrasound (EUS) is additionally used when MRI is not definitive to exclude early cT1/T2 disease in the lower third of the rectum or early cT3a/b tumors in the middle third of the rectum.
- •Spiral-CT of the abdomen and chest to exclude distant metastases.
- •Aged at least 18 years. No upper age limit.
- •WHO/ECOG Performance Status =1
- •Adequate haematological, hepatic, renal and metabolic function parameters:
- •- Leukocytes = 3.000/mm^3, ANC = 1.500/mm^3, platelets = 100.000/mm^3, Hb > 9 g/dl
- •- Serum creatinine = 1.5 x upper limit of normal
- •- Bilirubin = 2.0 mg/dl, SGOT-SGPT, and AP = 3 x upper limit of normal
- •Informed consent of the patient
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 304
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 304
排除标准
- •Lower border of the tumor localised more than 12 cm from the anocutaneous line as measured by rigid rectoscopy
- •Distant metastases (to be excluded by CT scan of the thorax and abdomen)
- •Prior antineoplastic therapy for rectal cancer
- •Prior radiotherapy of the pelvic region
- •Major surgery within the last 4 weeks prior to inclusion
- •Subject pregnant or breast feeding, or planning to become pregnant within 6 months after the end of treatment.
- •Subject (male or female) is not willing to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months (male or female) after the end of treatment
- •On-treatment participation in a clinical study in the period 30 days prior to inclusion
- •Previous or current drug abuse
- •Concomitant other antineoplastic therapy
- •Serious concomitant diseases, including neurologic or psychiatric disorders (incl. dementia and uncontrolled seizures), active, uncontrolled infections, active, disseminated coagulation disorder
- •Clinically significant cardiovascular disease in (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) = 6 months before enrolment.
- •Chronic diarrhea (> grade 1 according NCI CTCAE)
- •Prior or concurrent malignancy = 3 years prior to enrolment in study (Exception: non-melanoma skin cancer or cervical carcinoma FIGO stage 0-1), if the patient is continuously disease-free
- •Known allergic reactions on study medication
- •Known dihydropyrimidine dehydrogenase deficiency
- •Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
研究者
相似试验
尚未招募
1 期
Feasibility study of adjuvant chemotherapy in patients with oesophageal cancer who received neoadjuvant chemotherapy and underwent curative surgeryACTRN12616000554460South Adelaide Local Health Network32
招募中
2 期
Neoadjuvant Chemotherapy followed by Pre-operative Chemoradiation and Consolidation Chemotherapy before Surgery in High Risk Rectal Cancer: Multicentric Phase II Study2024-517183-31-00Centro Di Riferimento Oncologico Di Aviano93
已完成
2 期
Induction Chemotherapy and Adjuvant Thoracic Radiation in Resectable Stage N2-3A/3B Non-small Cell Lung Cancer (ICAT study)Resectable Stage 3A-N2 Non-small Cell Lung CancerJPRN-UMIN000025010Kyoto Prefectural University of Medicine1
进行中（未招募）
不适用
Phase II pilot study of a preoperative induction chemotherapy in combination with Bevacizumab followed by combined radiochemotherapy for patients with locally advanced rectal carcinomalocally advanced rectal cancer with high risk of recurrenceEUCTR2010-024354-11-ATABCSG (Austrian Breast & Colorectal Cancer Study Group)25
进行中（未招募）
不适用
Induction chemotherapy followed by chemoradiation with cetuximab and cisplatin for inoperable squamous cell carcinoma of the head and neck.Inoperable squamous cell carcinoma of the head and neck.EUCTR2006-003381-33-SIInstitute of Oncology Ljubljana